ChromaDex Executives to Participate in Lytham Partners 2024 Investor Select Conference
ChromaDex, a bioscience firm recognized for its expertise in nicotinamide adenine dinucleotide (NAD+) and healthy aging research, has confirmed participation of CEO Rob Fried and CFO Brianna Gerber at the Lytham Partners 2024 Investor Select Conference. Set to take place on February 1, 2024, the conference will highlight one-on-one virtual sessions with high-ranking executives, as revealed by our source – Reader Wall.
ChromaDex Leads the Charge in Healthy Aging Research
With a strong authority in the sector of healthy aging research and NAD+, ChromaDex has turned heads. The phenomenon of NAD+ levels naturally decreasing with age is drawing a lot of attention due to the profound implications on health and longevity. ChromaDex’s stand-out ingredient, Niagen, is an industrially produced form of nicotinamide riboside (NR), a precursor to NAD+. As the company owns the patent for nicotinamide riboside alongside other NAD+ precursors, it stands at the forefront of innovation in this sector.
NAD+ Redefining our Understanding of Aging
Findings by Dr. Michael Lustgarten that indicated increased NAD+ levels in response to nicotinic acid and NMN usage have sparked excitement in scientific circles. The emerging studies and trials concerning NAD+ synthesis, aging, and longevity only add to the potential value of such revelations. NMN’s ability to encourage cellular recovery and resilience, in addition to enhancing NAD+ levels critical for energy generation and cell health, is attracting increasingly more attention.
NMN’s Implications on Health and Longevity
Nicotinamide mononucleotide (NMN), a NAD+ precursor, is thought to be significantly influential to health and longevity. Securing the perfect dosage of NMN is of utmost importance, motivating a recommendation for people to seek guidance from healthcare practitioners prior to beginning any supplementation. The possible health advantages, safety protocols and effectiveness of NMN supplementation are currently under thorough investigation as part of ongoing research and clinical trials associated with NMN and healthy aging.
